Chronic Granulomatous Disease

ACTIMMUNE^® is the only therapy currently approved by the U.S. Food and Drug Administration for the reduction of the frequency and severity of serious infections related to chronic granulomatous disease (CGD). In clinical trials, ACTIMMUNE has been shown to be safe and effective in children and adults.

Compared with patients who received placebo, or inactive treatment, patients treated with ACTIMMUNE^® experienced:

• 67% reduction in the relative risk of serious infections
• 53% fewer primary infections
• 64% fewer infections overall
• 67% fewer inpatient hospital days

More Information

• Click here for an overview of CGD and ACTIMMUNE^® treatment

Severe, malignant osteopetrosis

ACTIMMUNE^® is the only medication approved by the U.S. Food and Drug Administration for delaying time to disease progression in patients with severe, malignant osteopetrosis. In clinical trials, patients receiving ACTIMMUNE® with or without calcitriol demonstrated evidence of increased bone resorption and enhanced bone marrow activity, as well as a reduction in the number of serious infections.

More Information

• Click here to learn more about osteopetrosis and ACTIMMUNE^® treatment

The most common adverse events observed in patients with CGD were flu-like symptoms (e.g., headache, fatigue, fever, myalgia, and rigors). Similar adverse events were observed in patients with severe malignant osteopetrosis. Please refer to the ACTIMMUNE® Safety section on this Web site for more complete safety information.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of patients.

For U.S. resident use only. The product discussed herein may have different product labeling in different countries. Please see the full U.S. Prescribing Information (pdf file).